Pharmaceuticals (Feb 2021)

Α Multicenter Retrospective Study Evaluating Brivaracetam in the Treatment of Epilepsies in Clinical Practice

  • Maria Stefanatou,
  • Eirini Vasileiadou Kapetanou,
  • Vasilios K. Kimiskidis,
  • Vasileios Papaliagkas,
  • Panagiotis Polychronopoulos,
  • Sofia Markoula,
  • Kleoniki Charisiou,
  • Dimitrios Kazis,
  • Anastasia Verentzioti,
  • Panayiotis Patrikelis,
  • Athanasia Alexoudi,
  • Stylianos Gatzonis

DOI
https://doi.org/10.3390/ph14020165
Journal volume & issue
Vol. 14, no. 2
p. 165

Abstract

Read online

Brivaracetam (BRV) is the latest approved antiepileptic drug. The aim of the study was to evaluate the efficacy and tolerability of BRV in everyday clinical practice. In this retrospective, observational, multicenter study, data from epilepsy patients receiving BRV from January 2018 to July 2019 were analyzed. Patients with age ≥16 suffering from any type of epilepsy and having at least one follow up encounter after dose titration were included. 156 consecutive patients were included in the study. The mean age was 40 (16–84 years) and the mean duration of epilepsy was 21 years. Of the 156 patients, 81% were diagnosed with focal-onset seizures, 16% with generalized seizures, while 3% suffered from unclassified seizures. Nine patients received BRV as monotherapy as a switching therapy. At the first follow up visit, seizure cessation was achieved in 56 (36%) patients and the rate of ≥50% responders was 36%. Twenty four patients (15%) remained unchanged; six patients (4%) were recorded with increased seizure frequency, while the remaining 9% had a response of less than 50%. Twenty-six patients (17%) showed clinically significant adverse events, but none were life threatening. Brivaracetam seems to be an effective, easy to use and safe antiepileptic drug in the clinical setting.

Keywords